Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

205.52 +0.04 (+0.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 Next >
News headline image
The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kura Announces Lifting Of Clinical Hold On Phase 1 Blood Cancer Study Kura... 
Via Benzinga
News headline image
Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
What 10 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗
Over the past 3 months, 10 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ: 
Via Benzinga
News headline image
The Week Ahead In Biotech (Jan. 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week ↗
Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference. Here are the key catalysts... 
Via Talk Markets
News headline image
The Week Ahead In Biotech (Jan 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week ↗
Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference. Swiss... 
Via Benzinga
News headline image
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks ↗
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year? 
Via Investor's Business Daily
News headline image
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Liver Function
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 3, 2022 ↗
Upgrades For nVent Electric PLC (NYSE:NVT), Vertica... 
Via Benzinga
News headline image
What 9 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ: 
Via Benzinga
News headline image
Alnylam to Webcast Presentation at 40th Annual J.P. Morgan Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates ↗
Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers Microbot Medical (NASDAQ:MBOT) stock moved upwards by 47.87% to $8.02 during Monday's regular session. The current volume of 63.6 million shares is 153229.83%... 
Via Benzinga
News headline image
51 Biggest Movers From Yesterday ↗
Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares climbed 65.1% to close at $8.95 on Monday after the company announced a strategic collaboration with Stryker Corporation to... 
Via Benzinga
News headline image
34 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares jumped 69.6% to $9.19 after the company announced a strategic collaboration with Stryker Corporation to develop the LIBERTY... 
Via Benzinga
News headline image
BridgeBio Pharma Stock Crashes As Pfizer-Rivaling Heart Drug Flops ↗
Patients who received the drug didn't improve in the six-minute walking test. 
Via Investor's Business Daily
News headline image
FDA Approves Alnylam - Novartis' Leqvio As the First siRNA To Reduce Bad Cholesterol ↗
The FDA has approved Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) Leqvio (inclisiran) to lower low-density lipoprotein cholesterol (LDL-C). Leqvio is... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug... 
Via Benzinga
News headline image
Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Publishes 3rd Annual Patient Access Philosophy Report Demonstrating Steady Access to Approved Therapies as Company Enters New Geographies
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients... 
Via Benzinga
News headline image
Alnylam Initiates Phase 2 Study of Lumasiran in Patients with Recurrent Kidney Stone Disease
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of Gout
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
2 Mid-Cap Biopharma Stocks BofA Securities Recommends For 2022 ↗
Biotech stocks are risky investments and to make a profit informed decision-making is needed. BofA Securities announced its ... 
Via Benzinga
News headline image
Alnylam Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
News headline image
Alnylam Ranks #1 in Boston Globe’s Top Places to Work List for 2021
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2
...
16 17 18 19 20 21 22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.